Is Aphria’s (TSX:APHA) Stock Ready to Soar?

Now that all the drama is in the rear-view mirror, is it the right time to buy Aphria Inc (TSX:APHA) (NYSE:APHA)?

question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Aphria Inc (TSX:APHA)(NYSE:APHA) has seen its share of drama over the past year. However, the pot company’s latest financial results were a breath of fresh air. Aphria finally put all its troubles behind and seems to be firing on all cylinders.

Could this be the start of a rally for the Ontario-based pot grower? Let’s look at what Aphria did during its fourth quarter. 

Revenues continue to soar

Aphria’s third-quarter financial results were somewhat disappointing, partly because of a lack of organic growth. The bulk of the firm’s top line increase was as a result of several international acquisitions.

Aphria’s core domestic operations were not impressive, but this may not be as big a problem as it seems.

It isn’t a secret that the Canadian pot market is highly competitive and risks suffering from a supply glut. Perhaps Aphria can keep its earnings afloat by relying on its international operations. 

During the fourth quarter, Aphria posted a net revenue of $128.6 million, which represents a sequential quarterly increase of 75% and a whopping 969% year-over-year jump.

Its average retail selling price for medical cannabis decreased by 4% sequentially, while its average retail selling price for recreational cannabis increased by 11%.

Once again, however, the lion’s share of the company’s net revenue was as a result of international acquisitions. Distribution revenue (which includes revenue from Aphria’s German-based subsidiary CC Pharma) accounted for almost $100 million (about 78%) of net revenue. Sales of cannabis produced were $33 million. 

Aphria delivers a profit

Aphria had to incur a one-time impairment charge related to the much discussed and much- criticized LATAM acquisitions. This charge cost the company $50 million in non-cash expenses, dragging the firm’s earnings down in the third quarter. The fourth quarter shows a very different picture.

To everyone’s surprise, Aphria managed to deliver a net profit of $15.760 million, or about $0.05 per share, which is a major improvement, both sequentially and compared to the corresponding period of the previous fiscal year. Most analysts expected Aphria to post a net loss in the neighbourhood of $0.05 per share.

For fiscal year 2020, Aphria expects to post revenues between $650 million and $700 million, which would represent an increase of about 174%-195% from fiscal year 2019.

The company also expects its earnings before taxes, expenses, depreciation and amortization (EBITDA) to be between $88 million and $95 million. 

Finally out of the shadows 

It looks like Aphria finally put all its demons aside and manage to deliver stellar financial results. Naturally, the firm was rewarded: its share price jumped by as much as 40% after its earnings report was released.

It might be worth considering purchasing shares of Aphria before they skyrocket.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny has no position in any of the stocks mentioned.  

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »